The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) traded higher in the premarket on Friday after The Washington ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

President Donald Trump sent letters to more than a dozen major drugmakers Thursday demanding that they lower the cost of ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Medicare Part D premiums are set to rise sharply as a key federal subsidy is scaled back. The Trump administration plans to ...

Technology giants Apple, Amazon and Google join Trump's plan to make it easier to share consumers health records.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

President Donald Trump wrote letters to at least 17 pharmaceutical companies Thursday demanding they lower drug prices for ...